Abstract-This paper reports a microfluidic-based telemedicine system for the determination of insulin, an important indicator for clinical diagnosis of diabetes. The telemedicine system conveys the assay results digitally to established healthcare facilities, where trained medical professionals can directly assist the detection process and provide diagnosis through the Internet. The integrated polydimethysiloxane (PDMS) microfluidic system consists of one pneumatic micropump and one micromixer on a single chip for insulin detection. The detection protocol is based on magnetic microbeads based double-antibody sandwich chemiluminescent immunoassay. The peak value of the luminous intensity is proportional to the insulin concentration of the testing sample. The sensitivity curves of the microfluidic system have been quantified, and the insulin detection limit is determined to be about 10 -11 M. The combination of PDMS microfluidic devices and a communication strategy offers new opportunities for diabetes care and screening, especially in rural areas, and the proposed system can be an extremely useful Point-of-Care diagnostic tool with off-site expert assistance.
I. INTRODUCTION
Diabetes mellitus (DM) is a prevalent chronic human disease caused by deficiency or diminished effectiveness of endogenous insulin, and diabetic patients bear a tremendous burden both physically, psychologically and economically [1] . Currently, the most popular clinical detection technique for diabetes is the blood glucose test. But for early diabetes diagnosis and discriminating among different types of diabetic patients, irregular blood glucose level is not a good indicator. Insulin is a peptide hormone that controls the glucose level in blood, and the determination of insulin level is more suited for early diagnosis of asymptomatic patients with pre-diabetes [2] . The standard test methods for insulin, including enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA), are usually based on microplates and automatic biochemistry analyzers. Although these methods are reliable, they require relatively large and expensive equipments. With the number of diabetic patients increasingly globally and especially in developing countries, providing a fast point-of-care testing tool for insulin has become increasingly important to public health.
Microfluidics is a promising technique to replace the conventional diagnostic systems for diabetes screening due to its advantages of low reagent consumption, short analysis time, and multi-process integration [3] [4] [5] . In microfluidic systems, sample pretreatment, reagent transportation, mixing, reaction, separation, detection and product collection can be effectively integrated and accomplished automatically on a single chip [6] . With their portability characteristic, microfluidic systems can be used outside of the hospital, and provide a great opportunity for widespread diabetes screening in the rural environment.
Telemedicine, an attractive communication tool for improving disease management between healthcare providers and patients, is officially defined as "any transmission of medical information by means of telecommunication technology" [7] . For diabetic patients, fast blood insulin measurement at home opens a new way to determine the state of the disease within a short period of time, but without timely professional feedback, it has somewhat of a lesser value [8] . Presently, along with the development of cyber technology, telemedicine is changing the existing models for public healthcare particularly in the way of service delivery [9] . Telemedicine based on the Internet offers an ideal solution for patients living in rural areas to obtain professional diagnosis without leaving their homes [10] . The combination of microfluidic devices and portable detectors capable of transmitting digital information through existing communication channels provides an integrated approach for point-of-care diabetes diagnosis and management [11] . This paper presents the development of a telemedicine system for diabetes patients, which quantifies insulin in PDMS based microfluidic devices and exchanges the test result with off-site specialists for medical evaluation. Compared with the microfluidic devices described in our previous publication [12] , the new microfluidic system integrates a pneumatic micropump with a micromixer and significantly decreases the dead volume of the detection system. By using the detection protocol of double-antibody sandwich chemiluminescent immunoassay, the integrated microfluidic system automates the process of immunoreactions based on magnetic micro beads, and utilizes a photometer to quantify the insulin captured by the immune beads in the micromixer. The developed microfluidic system is controlled both locally by a WiFi phone and remotely via the Internet, achieving the goal of local testing and processing while under the supervision of remote trained personnel. Medical doctors located off-site can then analyze the test result of the immune indicators and offer professional opinion.
II. TELEMEDICINE SYSTEM FRAMEWORK
The primary components of the telemedicine system include an integrated PDMS-based microfluidic chip, a chemiluminescence detection unit, a local control system and a wireless communication device such as a cellphone, capable of quantifying the results of the microfluidic system and transmitting the digitized information off-site through the Internet. After receiving and analyzing the test result, the physician remotely adjusts the control parameters of the microfluidic system when necessary, and provides medical opinion along with other related information.
A. Microfluidic-based Telemedicine System
Fig . 1 demonstrates the architecture of the microfluidic based telemedicine system. The microfluidic system carries out the immune reactions automatically; the local control system consists of a control circuit and a mini air pressure pump for adjusting the performance of the microfluidic pump and micromixer. A photometer measures the luminous intensity of the chemiluminescent immunoassay in the microfluidic system. As a communication tool, a WiFi phone conveys the control parameters and test results through the Internet, and these results are displayed on the monitor of the diabetes specialist's computer. The role of the off-site physician would be to analyze the data and to recommend treatment. Fig. 2 shows the hardware design of the local control circuit for regulating the frequency of the electromagnetic valves (EMV) that control the air pressure delivered to the micropump and micromixer. The Samsung S3C2440 embedded processor is a highly integrated control chip, especially suitable for handheld devices since it can be powered by batteries. The control frequency is shown on the liquid crystal display (LCD); the power amplifier elevates the output signals to the level that can drive the EMV. Utilizing WiFi wireless local area network communication, the cell phone can adjust the frequency of the EMV control signals. The same cell phone is also responsible of data collecting from the insulin measurement and conveying this information to the operator. A mini air compressor (D730A-23-01, HARGRAVES, USA) supplies compressed air to the pneumatic micropump and micromixer, and a pressure sensor (DPG1000B-100G, OMEGA, USA) is utilized to monitor the air pressure. Fig. 3a is a schematic illustration of the microfluidic chip. The integrated microfluidic chip is composed of one pneumatic micropump and one micromixer. It consists of two inlets and one outlet for transporting the ample fluids. Externally generated copressed air is injected into the air chambers of the micropump and micromixer to individually actuate them. The exploded view of the microfluidic chip is showed in Fig. 3b . The chip consists of one glass substrate (0.5mm thick) and two separate PDMS layers: a liquid microchannel layer (about 4mm thick) and a pneumatic air chamber layer (about 0.2mm thick). The microchannel layer contains a 100μm-tall microchannel and a 2mm-diameter mixing chamber. The air chamber layer consists of four membrane-enclosed air chambers for sample pumping and six air chambers connected in series for sample mixing. The thickness of the pneumatic membrane in the air chamber PDMS layer is approximately 100 m. A photograph of the integrated microfluidic chip for insulin detection is shown in Fig. 3c . The overall dimensions of the chip are measured to be 38mm by 40mm.
B. Local Control System

III. MATERIALS AND METHODS
A. Microfluidic Chip Design
The working principles of the pneumatic micropump and micromixer are similar. Air pulses produced by the local control system deflect the pneumatic membrane in the air chamber PDMS layer in a sequential manner, causing either fluid flow in the micropump or mixing in the micromixer. The flow rate of the micropump and the mixing efficiency of the micromixer are largely determined by the pressure and frequency of the air pulses. 
B. Microfluidic Chip Fabrication
The fabrication process of the microfluidic chip as demonstrated in Fig. 4 is based on computer numerical controlled (CNC) machining of micromolds, PDMS casting and replication, and PDMS-to-PDMS and PDMS-to-glass bonding. First, polymethylmethacrylate (PMMA) micromolds with the desired structures of the micropump and micromixer are fabricated using a CNC miller (EGX-400, Roland Inc., Japan). Then liquid PDMS is prepared by mixing the PDMS (Sylgard® 184, Dow Corning, USA) pre-polymer with a curing agent in a ratio of 10:1. After deaerating the mixed polmer under vacuum, the mixture is poured onto the fabricated micromolds and cured. Next, the hardened PDMS structures are removed from the PMMA molds and a short oxygen plasma treatment is performed to bond the microchannel PDMS layer to the air chamber PDMS layer. Finally, using another short oxygen plasma treatment, the bonded PDMS structures and a matching glass substrate are bonded together to complete the microfluidic chip. The interior of the PDMS microchannel and microreservoir is treated with bovine serum albumin (BSA) to reduce protein and magnetic bead adsorption during the immunoassay. 
C. Detection Protocol
The microfluidic system is designed and fabricated for rapid detection of insulin through chemiluminescent immunoassay. Fig. 5a is an illustration of the various components involved in the formation of the sandwich-based immunoassay. The anti-insulin antibodies are connected to the super paramagnetic beads through carboxyl groups. The procedure of the magnetic-bead based chemiluminescent immunoassay for heterogeneous insulin detection is presented in Fig. 5b . Taking advantage of the specific interaction between the anti-insulin coated beads and insulin antigen, the insulin molecules are first recognized in the analyte of the micromixing chamber, leading to the formation of the semisandwich structures. A washing procedure is then carried out with the help of a permanent magnet which is fixed to the outer surface of the mixing chamber. This procedure purifies the sample by removing the interfering substances. After that, horseradish peroxidase (HRP) labeled insulin antibodies are added to form the complete sandwich complexes. By the use of another external magnet, the non-reactive HRP labeled insulin antibodies are washed away. Next, the chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific, USA) including luminol with an enhancer and hydrogen peroxide (H 2 O 2 ) are injected. Catalyzed by the HRP of the sandwich complexes, the luminol emits a light (wavelength ~ 425nm) with an intensity that is proportional to the amount of the HRP present in the sample. Since the insulin and its secondary antibody are in a one-to-one conjugation, the quantity of HRP connected to the secondary antibody is a direct measurement of the quantity of the insulin. The emitted light is quantified by the photometer. Additional details of the detection protocol can be found in [13] .
(c)
The complete immune reaction is carried out in the PDMS microfluidic system. In the conventional biochemistry analyzers, the immune magnetic beads and biosamples are incubated for 60 min to recognize the target insulin. And the HRP-labeled insulin antibodies are then allowed to interact with the target insulin for 30 minutes. When compared this technique, the microfluidic system requires less reagents and shorter reaction time. 
IV. EXPERIMENTAL RESULTS
To reduce noise and improve sensitivity, the microfluidic chip is placed in the dark box of the photometer when adopting the chemiluminescent method to determine the insulin antigen between the immune beads and HRP labeled antibodies. Fig. 6 shows the sensitivity curve of the insulin immunoassay, demonstrating the relationship between the intensity of the emit light in RLU and the insulin concentration. As indicated by the figure, the insulin detection limit of the microfluidic system is about 5×10 -11 M. The insulin concentration forms a relatively linear relationship with the chemiluminescent light intensity with a linear range of 5 10 -11 M -1.6 10 -9 M. By decreasing the dead volume, the detection limit of the new integrated microfluidic system has been improved when compared to our previous design.
The pneumatic micropump and micromixer of the microfluidic chip are operated at the optimal working parameters. Through the two inlets, solutions are fed into the mixing chamber, and allowed to achieve complete reaction. The detection time is about 10 min, which is much faster than that of the conventional methods for insulin detection. 
V. CONCLUSIONS
A cyber-based telemedicine system for insulin measurement using a PDMS microfluidic chip has been demonstrated. Through the Internet for data transmission, this detection method provides a new technique to advance primary healthcare by supporting diagnostics and monitoring of insulin status for DM at remote locations that lack dependable testing facilities and trained physicians. The integrated microfluidic chip utilizes one pneumatic micropump and one micromixer, and the insulin detection limit is determined to be about 10 -11 M. When compared to the conventional method, the microfluidic based telemedicine system is ideally suited for conducting large-scale diabetes screening of the general population. Further studies will be carried out to validate these designs and to promote telemedicine as an opportunity for better diabetic patient care.
